RCS - Digostics Limited - NHS Hospital Trust Pilot of New Testing Technology

Mitsui & CoAnnouncement

19/04/2023 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230419:nRSS6000Wa&default-theme=true

RNS Number : 6000W  Digostics Limited  19 April 2023

NHS Hospital Trust Pilot of New Testing Technology Sees Pregnant Women in
Southampton Become the First Patients Globally to Access Gestational Diabetes
Testing at Home

UHS Partners with Digostics to Launch the World's First Home Testing Service
for Gestational Diabetes

OXFORD, UK / ACCESSWIRE / April 19, 2023 / Digital clinical diagnostics and
diabetes home testing provider Digostics and University Hospital Southampton
NHS Foundation Trust (UHS) announced today a partnership that will see
expectant mothers under the care of UHS maternity services become the first,
anywhere in the world, to access ground-breaking new remote testing technology
designed to improve screening for gestational diabetes mellitus (GDM). The
collaboration involves a pilot introduction of the only regulatory-approved
home-use oral glucose tolerance test (OGTT) testing-solution, GTT@home,
developed by Digostics.

"We hope this revolutionary new at-home test is going to dramatically change
the way we deliver gestational diabetes testing during antenatal care," said
Matthew Coleman, Consultant Obstetrician, UHS. "Not only is it better for the
patients to self-test in the convenience of their own home, cutting down the
number of antenatal appointments they attend, but it will also free up
precious NHS time and resources."

According to the International Diabetes Federation, up to 20%( 1 ) of UK
pregnancies are impacted by GDM, with background risk factors 2  including the
age, ethnicity and body mass index of the expectant mother. Left undiagnosed
or untreated, GDM can lead to perinatal complications such as foetal
macrosomia (larger than average babies) that warrant unscheduled or even
emergency changes to the birth-plan to protect both mother and baby.
Additionally, 50% 3  of women experiencing GDM can go on to develop type 2
diabetes (T2D) within 10 years. The condition also confers an 8-fold 4 
increase for the child of developing T2D in adulthood. Prompt identification
of GDM is key.

"Digostics is excited to work with UHS to explore how GDM screening can be
streamlined through home-testing," said James Jackson, CEO and Founder,
Digostics. "Our aim is to demonstrate how we can transform diabetes detection
in pregnancy by taking the OGTT to the expectant mother, resulting in
increased test uptake, reductions in test overheads for healthcare providers
and the earlier return of GDM diagnoses."

The OGTT - a fasting test involving an initial blood test, the immediate
consumption of a glucose drink and then a second blood test after a two hour
wait - is the only recommended test for detecting GDM. However, as the OGTT is
currently offered only in-clinic, the inconvenience for patients and the
provisioning challenges posed for healthcare providers frequently constrains
test throughput and can lead to delayed testing.

"From the admin resources it takes to book and manage clinics, the clinical
time taken to run the service and the clinic space taken, this can all now be
done with a simple test at home using the GTT@home kit," added Matthew
Coleman. "In addition, patients are able to test at the earliest opportunity,
meaning fewer delays and, if gestational diabetes is detected, they can be
treated and managed quickly helping to keep them and their babies safe."

The GTT@home service is based on a simple-to-use home test kit containing the
novel GTT@home test device, a glucose drink and finger prickers. The test kit
is mailed to the expectant mother at the time the test is due. Easy to follow
instructions, online guidance and telephone support ensure that the test can
be completed conveniently at home on the day of choice.

When completed, the user can immediately send their test data to their care
team by scanning a snap-off fob attached to the test device with a smartphone
using the GTT@home mobile app. This is enabled by the near field communication
(NFC) functionality within the device, with the process akin to making a
contactless mobile payment in a store. Alternatively, the patient can post the
fob in the supplied prepaid envelope for processing.

The GTT@home testing service also includes a software platform that enables
the antenatal care team to schedule tests and view patient results.

Key aims of the collaboration include improving healthcare equity of access
and reducing health inequalities by eliminating barriers associated with
in-clinic testing that can be felt more acutely within specific at-risk
patient cohorts. To support this, Digostics is creating multilingual home-user
support.

"We also hope that testing at home proves to be appealing to the complete
background social and demographic populations that we work with and we look
forward to receiving feedback from those involved in the next phase of
research." further explained Matthew Coleman.

GTT@home achieved UKCA and CE market authorisation in 2022, becoming the first
and only regulatory approved alternative to the in-clinic OGTT. A first phase
pilot of GTT@home involving a small caseload of patients was conducted with
UHS in November 2022. This announcement reflects the move to a higher volume
second-phase project designed to prove the service's overall effectiveness.

"With this pilot representing a global-first, UHS' international reputation
for clinical innovation makes it the perfect partner for this project." said
Oenone Duroe, UK Market Access Director, Digostics. "We hope a successful
pilot will see maternity services at other NHS trusts take their cue from UHS
and explore the merits of GTT@home for diabetes home-testing."

About Digostics

Far too many people, in all geographies, are living with undiagnosed diabetes.

Digostics' mission is to enable healthcare providers to detect everyone with
diabetes, and those at risk of developing diabetes, by eliminating the common
barriers that inhibit testing and prevent the timely return of accurate
diagnoses.

Digostics is proud to offer GTT@home - the most accessible and scalable way
for clinical teams to realise their diabetes testing objectives.

For more information visit www.digostics.com
(http://www.digostics.com/?utm_source=Press%20Release&utm_name=UHS&utm_medium=Hubspot%20Landing%20Page)

About University Hospital Southampton NHS Foundation Trust

University Hospital Southampton NHS Foundation Trust (UHS) is one of the
largest acute teaching trusts in England with a turnover of more than £1.15
billion in 2021/22. UHS provides hospital services for 1.9 million people
living in southern Hampshire and specialist services - including
neurosciences, respiratory medicine, cancer, cardiovascular, obstetrics and
specialist children's services - to more than 3.7 million people in central
southern England and the Channel Islands. Southampton General Hospital is a
designated major trauma centre serving the Wessex Region and Channel Islands
and is one of only two places in the south of England to offer adults and
children full onsite major trauma care provision.

Every year more than 13,000 staff see 650,000 people at outpatient
appointments, deal with 150,000 attendances at the emergency department and
treat 160,000 admitted emergency, inpatient or day case patients. In addition,
the trust delivers more than 100 outpatient clinics across the south of
England to keep services local for patients. Providing these services costs
£2.7 million per day.

Following the Care Quality Commission's most recent inspection (report
published in April 2019), all sites and services across UHS are now rated as
'good' or 'outstanding' in the effective and caring domains. Overall, the
trust received a 'good' rating - and 'outstanding' for providing effective
services. Among individual services, the CQC rated urgent and emergency
services, medical care, surgery, services for children and young people and
end of life care 'good', with critical care 'outstanding'. To view the full
report, visit www.cqc.org.uk/provider/RHM/reports (https://pr.report/HBRoIySZ)
.

UHS is consistently one of the UK's highest recruiting trusts of patients to
clinical trials and in the top ten nationally for research study volume as
ranked by the NIHR Clinical Research Network. In partnership with the
University of Southampton, UHS has £27 million of NIHR infrastructure
dedicated to bringing the latest treatments to patients. For more information,
visit www.uhs.nhs.uk/ClinicalResearchinSouthampton
(https://pr.report/72HDje5U) .

To help shape the future of hospital services and raise issues that are
important to patients, families and visitors, become a UHS member. Anyone
interested in finding out more or joining can contact the membership office on
www.uhs.nhs.uk/members (https://pr.report/HE3q6MCl) .

Follow us on Twitter (https://pr.report/SGgFr3UQ) , Facebook
(https://pr.report/yn493aQU) , Instagram (https://pr.report/uh-fc3O2) and
LinkedIn (https://pr.report/3znSfNM0) for all the latest news updates.

Southampton Hospitals Charity enhances the care and treatment of our patients
by raising funds to support areas that lie beyond the scope of NHS funding.
For more information, visit www.southamptonhospitalscharity.org
(https://pr.report/hE1Kgkcv)

Media Contact(s)

Graeme Collins, Digostics

Mobile: +44 (0)7854 664168

Email: gc@digostics.com (mailto:gc@digostics.com)

University Hospital Southampton NHS Foundation Trust

Email: communications@uhs.nhs.uk (mailto:communications@uhs.nhs.uk)

( 1 ) International Diabetes Federation Diabetes Atlas 10(th) Edition 2021

 2  NHS - Gestational Diabetes Overview

 3  International Diabetes Federation - Gestational Diabetes - Care &
Prevention 2020

 4  Pub Med - Future Risk of Diabetes in Mother and Child After Gestational
Diabetes Mellitus 2009

SOURCE: Digostics Limited

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGZGMDGRLGFZM